Surfaceome analysis of Australian epidemic Bordetella pertussis reveals potential vaccine antigens.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
16 01 2020
Historique:
received: 15 07 2019
revised: 18 10 2019
accepted: 22 10 2019
pubmed: 11 11 2019
medline: 13 2 2021
entrez: 10 11 2019
Statut: ppublish

Résumé

Since acellular vaccines (ACV) were introduced in Australia, epidemic Bordetella pertussis strains changed from single nucleotide polymorphism (SNP) cluster II to SNP cluster I. Our previous proteomic analysis identified potential proteomic adaptations in the whole cell and secretome of SNP cluster I. Additionally, current ACVs were shown to be less efficacious against cluster I in mice models and there is a pressing need to discover new antigens to improve the ACV. One important source of novel antigens is the surfaceome. Therefore, in this study we established surface shaving in B. pertussis to compare the surfaceome of SNP cluster I (L1423) and II (L1191), and identify novel surface antigens for vaccine development. Surface shaving using 1 μg of trypsin for 5 min identified 126 proteins with the most abundant being virulence-associated and known outer membrane proteins. Cell viability counts showed minimal lysis from shaving. The proportion of immunogenic proteins was higher in the surfaceome than in the whole cell and secretome. Key differences in the surfaceome were identified between SNP cluster I and II, consistent with those identified in the whole cell proteome and secretome. These differences include unique transport proteins and decreased immunogenic proteins in L1423, and provides further evidence of proteomic adaptation in SNP cluster I. Finally, a comparison of proteins in each sub-proteome identified 22 common proteins. These included 11 virulence proteins (Prn, PtxA, FhaB, CyaA, TcfA, SphB1, Vag8, BrkA, BopD, Bsp22 and BipA) and 11 housekeeping proteins (TuF, CtpA, TsF, OmpH, GltA, SucC, SucD, FusA, GroEL, BP3330 and BP3561) which were immunogenic, essential and consistently expressed thus demonstrating their potential as future targets. This study established surface shaving in B. pertussis, confirmed key expression differences and identified unknown surface proteins which may be potential vaccine antigens.

Identifiants

pubmed: 31703933
pii: S0264-410X(19)31442-2
doi: 10.1016/j.vaccine.2019.10.062
pii:
doi:

Substances chimiques

Antigens, Bacterial 0
Bacterial Outer Membrane Proteins 0
Pertussis Vaccine 0
Virulence Factors, Bordetella 0
Trypsin EC 3.4.21.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

539-548

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Laurence Don Wai Luu (LDW)

School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia.

Sophie Octavia (S)

School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia.

Chelsea Aitken (C)

School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia.

Ling Zhong (L)

Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, New South Wales, Australia.

Mark J Raftery (MJ)

Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, New South Wales, Australia.

Vitali Sintchenko (V)

Centre for Infectious Diseases and Microbiology-Public Health, Institute of Clinical Pathology and Medical Research - Pathology West, Westmead Hospital, New South Wales, Australia; Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney Medical School, University of Sydney, New South Wales, Australia.

Ruiting Lan (R)

School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: r.lan@unsw.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH